The public number of “Jinling Pancreatic Cancer Collaborative Group” is finally online! Biliary and pancreatic malignancies are common fatal cancers of the digestive system, and pancreatic cancer in particular is one of the malignancies with the worst prognosis. In the United States, the mortality rate of pancreatic cancer was the fourth highest among all malignant tumors in 2013, and the latest study predicts that the mortality rate of pancreatic cancer will rise to the second highest among all malignant tumors by 2030. In recent years, the incidence of pancreatic cancer has increased significantly in large and medium-sized cities in China, and the incidence in high-incidence areas such as Shanghai and Tianjin has increased fourfold in 20 years. However, because of the insidious onset of biliopancreatic malignancies, non-specific clinical manifestations and rapid disease progression, most patients are already in advanced stages or have distant metastases when diagnosed, and the 5-year survival rate of advanced bile duct cancer and pancreatic cancer is less than 5%, and the overall outcome is extremely poor. Radical surgery is the only treatment for patients with bile duct cancer and pancreatic cancer to obtain long-term survival. In view of the high risk of surgery and high complication rate, the success rate of radical surgery for biliary and pancreatic malignancies is an important indicator of the level of hepatobiliary surgery in a general hospital. However, only 10%-15% of patients have the chance of surgical resection when diagnosed, and their 5-year survival rate after surgery is about 20%. Only about 50% of patients evaluated as resectable before surgery eventually undergo radical resection, and the rest of patients often give up radical surgery because of intraoperative metastasis or tumor invasion by large blood vessels. Therefore, to improve the early diagnosis rate and to establish a multidisciplinary and comprehensive treatment plan centering on surgery is the current frontier of pancreatic cancer treatment. In order to improve the comprehensive diagnosis and treatment of biliopancreatic malignant tumors in our hospital, the Institute of General Surgery has established an innovative “surgery-centered multidisciplinary comprehensive treatment strategy for biliopancreatic tumors” with the innovative concept of “building our hospital into a research-oriented hospital” and has achieved initial success. In order to improve the level of comprehensive diagnosis and treatment of biliary and pancreatic malignant tumors in our hospital, we have established an innovative “multidisciplinary comprehensive treatment strategy for biliary and pancreatic tumors centered on surgery” and achieved initial success, which is reflected in the following innovations: 1. On 2014-05-21, the Institute of General Surgery and the Department of Gastroenterology jointly opened the “Comprehensive Jaundice Clinic (Biliopancreatic Tumor)”, which not only opens a green channel for patients with biliopancreatic tumors, but also provides “one-stop service”. The “one-stop service” not only opens up a green channel for patients with biliary and pancreatic tumors, but also eliminates the previous fragmentation of medical and surgical treatment, greatly shortens the pre-hospital diagnosis time for patients, and gains valuable time for the early establishment of a multidisciplinary comprehensive diagnosis and treatment plan centering on surgery; and the biliary and pancreatic tumor treatment team led by Director Li Ning personally extends the latest diagnosis and treatment technology and clinical thinking directly to the forefront of patient consultation, effectively improving the level of diagnosis and treatment of jaundice (biliary and pancreatic tumors). The “Multidisciplinary Biliopancreatic Malignant Tumor Seminar” led by Academician Li Jieshou every Thursday at 9:00 a.m. has further improved the “surgery-centered multidisciplinary comprehensive biliopancreatic tumor treatment system”, which has helped to establish the “Multidisciplinary Biliopancreatic Tumor Treatment System” in the future. It laid a solid foundation for the establishment of “Biliopancreatic Tumor Multidisciplinary Treatment Center” in the future, and further expanded the social influence and academic status of our hospital in related fields. At present, the clinic has been opened for 10 months, and nearly 350 patients have been seen, of which about 80% are referred from other general specialist clinics, while 40% are referred from outside hospitals, and many of them are referred from tertiary hospitals or teaching hospitals. Regarding the transfer of patients, about 30% of them are admitted to gastroenterology, 60% are admitted to general surgery, and the remaining 10% are followed up by outpatient clinics, and about 1/3 of the patients initially admitted to gastroenterology are later referred to general surgery for surgical treatment. 2. We have innovatively optimized the perioperative management strategy of radical surgery for biliary and pancreatic malignancies, especially the concept of “pancreaticoduodenectomy”, which has greatly reduced the rate of surgical complications and significantly improved the success rate of radical surgery. In order to improve the diagnosis and treatment of hepatobiliary surgery in our hospital, the Institute of General Surgery sent Dr. Wang Xinbo, deputy director of the Institute, to the University of California, Los Angeles (UCLA) University Medical Center for one year from 2012.07 to 2013.07, focusing on the comprehensive diagnosis and treatment of hepatobiliary surgery and biliopancreatic tumors. Since the second half of 2013, the Department of General Surgery has been optimizing the perioperative treatment strategy for all pancreaticoduodenectomies based on the previous clinical practice work and drawing on international advanced concepts, and then performing accelerated recovery in the perioperative period (ERAS) management for pancreaticoduodenectomy, with the main contents being perioperative restrictive fluid therapy, prophylactic antibiotic application strategy for 24 hours only, malignant obstructive jaundice, strategy for selecting preoperative yellowing reduction guidelines and methods, strategy for monitoring perioperative malnutrition and management of nutritional support, strategy for monitoring coagulation and target-guided therapy with thromboelastography (TEG), strategy for prophylactic application of tranexamic acid, strategy for multimodal analgesia, etc. The perioperative ERAS strategy of pancreaticoduodenectomy has not only greatly reduced the rate of surgical complications, especially the incidence of clinically significant pancreatic fistula is basically zero; but also significantly shortened the operating time, from only one pancreaticoduodenectomy per day in the past, a single medical group can now safely perform two or even three pancreaticoduodenectomies per day. More importantly, we have standardized the operation procedure of pancreaticoduodenectomy, which has significantly improved the success rate of radical surgery and laid the foundation for improving the long-term prognosis of patients with biliopancreatic malignancies. In the past two years, we have not only published five SCI papers, but also Vice Director Wang Xinbo gave a speech at the 11th Annual Meeting of the International Hepatobiliary and Pancreatic Association held in Seoul, Korea in March this year, which further enhanced the academic influence of our hospital in international hepatobiliary and pancreatic surgery. We have carried out innovative research on the criteria of critical resectability of biliary and pancreatic malignant tumors and the application of neoadjuvant therapy in biliary and pancreatic malignant tumors and basic research, and basically improved the construction of the “surgery-centered multidisciplinary comprehensive treatment system for biliary and pancreatic tumors”. 4. Now we have opened “Jinling Pancreatic Cancer Collaborative Group” WeChat work number, which is dedicated to providing the most comprehensive consultation and the latest research progress on biliary and pancreatic tumors, building an unobstructed communication platform between doctors and patients, and better serving the patients.